Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Healthcare buyouts boom in Asia

Bain & Company’s seventh Global Healthcare Private Equity and Corporate M&A Report shows that Asia Pacific deals last year surged to their highest levels since 2001.

It was a banner year for healthcare buyouts in Asia Pacific, with total disclosed deal value surging to US$7.2 billion, more than two times the 2016 level. Deal count rose to 61 from 52 in 2016. Five of those deals were in the sweet spot for large PE funds (US$0.5 billion-US$5 billion), compared with just one such transaction in 2016. Investors, both those domiciled in the region and those based elsewhere, invested in front of demographic and macroeconomic tailwinds, supported by loosening regulations in some markets.

The hottest sectors were biopharma and medtech, which together comprised 64% of deal value and 60% of deal count, with transactions in both developed markets, such as Australia and South Korea, and emerging markets, such as China and India. In a major biopharma deal, Carlyle Asia and Pacifi c Equity Partners acquired iNova Pharmaceuticals, an Australian company that makes both prescription and over-the-counter (OTC) products, for US$930 million. (Australia remained an active market; three of the top six Asia Pacific deals involved an Australian acquirer or target.) In medtech, a consortium of Chinese investors acquired a stake in Shanghai United Imaging Healthcare, a leading Chinese medical equipment and IT solutions provider.

Investors were also active in the provider sector, especially in specialty care formats. Australian-based KKR acquired Laser Clinics Australia, a retail chain of more than 80 hair removal and cosmetic clinics.

Many large global investors are showing continued interest in the Asia Pacific growth story. For example, Bain Capital invested about US$800 million to take a controlling stake in Hugel, a manufacturer of botulinum toxin. The trend continued into 2018; in January, European fund Permira bought I-Med, an Australian diagnostic imaging company, from EQT.

In China, PE investors took advantage of new regulations promoting the restructuring of the distributor system for drugs and devices. The rules, which aim to simplify the system by eliminating multiple layers of intermediaries and replacing them with just two invoices, have put many assets into play. For example, in a deal that attracted interest from both PE funds and corporate buyers, US-based Cardinal Health divested its Chinese distribution business, ultimately selling it to Shanghai Pharma, one of China’s largest pharmaceutical distributors.

As the Chinese government takes measures to encourage the development of the country’s healthcare infrastructure as part of the Healthy China 2030 effort, Chinese investors are looking abroad to Australia, Europe and the US, seeking category-leading platforms that have the potential to expand in China as well as in their home markets. For example, Chinese medtech company Beijing Wandong Medical Technology and PE fund Shanghai Yunfeng Xinchuang Investment Management collaborated with other investors to acquire Italian medical imaging company Esaote both to capitalise on opportunities in Europe and bring sophisticated imaging technology to China. Investment by China-domiciled PE funds in targets outside China spiked in 2016 and 2017, according to an analysis conducted by Bain.

In many cross-border deals, the Chinese funds teamed up with international funds or corporate players to further augment local market expertise and access. Chinese fund Hillhouse Capital partnered with American fund Clayton, Dubilier & Rice (CD&R) in the US$800 million acquisition of US-based Carestream Health’s digital dental business. In another cross-border partnership, China’s Pagoda Investment teamed up with Goldman Sachs Principal Investment Area and the Australian state pension fund Queensland Investment Corporation (QIC) to buy Sydney-based cancer care provider Icon Group from Quadrant Private Equity for a reported US$740 million.

Across Asia Pacific, not just in China, funds are increasingly banding together in consortiums, often across borders. Deal sizes, while still relatively small, are growing. Since 2014, the average size of healthcare PE buyouts in Asia Pacific has increased by 50%, from nearly US$80 million to nearly US$120 million, and funds are forming transnational partnerships to bring together capital and local capabilities. Eager to be a part of these cross-border consortium deals, Asian PE investors have channelled more resources into healthcare. Among all the dollars Asian PE funds have raised for new investments, the share raised by funds with a healthcare focus has more than tripled over the past decade.

Throughout Asia Pacific, exit activity in 2017 remained on par with previous years, with funds selling assets to a mix of other financial investors and corporate players across developed and developing markets. In addition, US-based funds engaging in exits found willing buyers among Asian corporates. For example, North American investor RoundTable Healthcare Partners sold Argon Medical Devices, a US-based medical device company, to Chinese medical group Shandong Weigao.

Bain expects investor activity in Asia Pacific to remain robust in 2018, with funds continuing to team up with other financial investors and corporate buyers. The cross-border trend is likely to intensify as Asian investors increasingly eye targets outside the region. Along with ongoing interest in the traditionally strong pharma and provider sectors, the market may see opportunistic medtech assets come onto the market. Favourable demographic and regulatory trends will continue to fuel interest in this growing, dynamic region, as the more than 50 funds active in Asia Pacific seek out new ways to deploy the large amount of dry powder they raised in 2017.

Posted on: 25/04/2018 UTC+08:00


StarMed@Farrer Square, the subsidiary of SGX-listed private healthcare provider Health Management International, has agreed to buy additional units in Farrer Square for S$36.7 million (US$26.7 million).
Orthopaedic specialists Asian Healthcare Specialists (AHS) has signed an investment agreement with Vanda 1 Investments, which is managed and controlled by Temasek Holdings unit Heliconia Capital Management.
Medical technology company Medmain has announced the alpha testing of its ground-breaking, pathology diagnostic software: PidPort. This was originally developed in Japan to enable precise and incredibly fast diagnosis of human body pathologies of all types, with most diagnoses completed in less than one minute. Medmain recently began testing the software in hospital sites in Japan, Thailand and Estonia.
Medical diagnostic imaging services provider Capitol Health has acquired a further two clinics in South West WA, which trade under the name West Coast Radiology and service the high-growth area surrounding Eaton (close to Bunbury) and Busselton.
China's Ping An Good Doctor (PAGD) announced its cooperation with more than 100 First-Class Hospitals at Grade III in China, including the 303th Hospital of Chinese People's Liberation Army, Qingdao Eye Hospital, the First Affiliated Hospital of Jinan University and the Third Affiliated Hospital of Southern Medical University, to build comprehensive "smart hospitals". At present, Ping An Good Doctor covers more than 1 million outpatients per day, effectively reducing the burden on hospitals, doctors, patients and the government.
Global alternative asset manager The Carlyle Group together with Meinian Onehealth Healthcare Holdings has invested in and become the single largest shareholder of Adicon, one of the largest independent clinical laboratory companies in China.
RepliCel Life Sciences, a company developing next-generation technologies in aesthetics and orthopaedics, has raised C$5.1 million (US$3.8 million) from YOFOTO (China) Health Industry.
China's Ping An Good Doctor (PAGD) has announced a strategic partnership with Zhongxin Pharmaceuticals. The two parties will build an online cardiovascular disease management centre in China.


Abrar Mir is that rare thing in the healthcare sector: a voice of reason. It notable that when he speaks at conferences, the chatter outside the auditorium diminishes and seats suddenly become hard to find. Part of this is thanks to his position as managing partner of Singapore-based private equity fund Quadria Healthcare, which he co-founded in 2012. But as much of it is due to his quiet authority and passion, as it is to the US$1.5 billion he has under management across the Asia Pacific region.
SOHO Global Health was founded in 1946 in Jakarta by Tan Tjhoen Lim as an injectables-focused pharmaceutical company. Today it is one of the largest pharmaceutical manufacturing and distribution businesses in Indonesia with a network that covers more than 80% of the hospitals and 90% of the pharmacies in the country.
Anupa Naik speaks nineteen to the dozen. The chief executive of Symple Wellness, a healthcare company set up in Singapore in July last year as an offshoot of the family office AJ Capital, has barely stood still since then, and shows no sign of stopping any time soon.
After listing on the Hong Kong Stock Exchange at the beginning of May, Ping An Healthcare and Technology, formerly known as Good Doctor, shows no sign of slowing down.
Amy Khor, senior minister of state, ministry of health in Singapore, looks at the challenges of how to deliver healthcare in the future.
First you must find a clinic space from which to practice. The good news is that space is available at most hospitals. The bad news is that a 1,200 square-foot clinic space at Mount Elizabeth Hospital currently retails for around S$10 million, or US$7.34 million to secure a space less than half the size of a tennis court. By the time you add fittings, equipment and staff, your relationship with your bank manager will likely be under severe strain.
China’s hospital landscape is rapidly changing as operators and owners respond to shifting policy incentives, an aging population, the opportunity to serve Tier 2 and 3 cities, and shifts in consumer preferences.
Today, more and more people are suffering from serious, incurable, and/or rare illnesses. However, access to information on such conditions has been quite limited, to hospitals or internet surfing. Even though there were communities and organizations serving people with certain illnesses, information was not widely available, due to the general nature of the illnesses.
my images


HealthInvestor Asia twitter feed